Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Position Increased by Lecap Asset Management Ltd.

Lecap Asset Management Ltd. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 42.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,072 shares of the company’s stock after acquiring an additional 2,412 shares during the period. Lecap Asset Management Ltd.’s holdings in Neurocrine Biosciences were worth $930,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of NBIX. Stanley Laman Group Ltd. increased its stake in Neurocrine Biosciences by 36.8% in the third quarter. Stanley Laman Group Ltd. now owns 37,531 shares of the company’s stock valued at $4,324,000 after acquiring an additional 10,088 shares during the period. Raymond James & Associates increased its holdings in shares of Neurocrine Biosciences by 4.3% in the third quarter. Raymond James & Associates now owns 62,446 shares of the company’s stock valued at $7,195,000 after purchasing an additional 2,552 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the period. Trust Point Inc. lifted its holdings in Neurocrine Biosciences by 22.0% in the third quarter. Trust Point Inc. now owns 1,935 shares of the company’s stock valued at $223,000 after buying an additional 349 shares during the period. Finally, nVerses Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $392,000. 92.59% of the stock is owned by institutional investors.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares in the company, valued at approximately $5,499,554.79. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Ingrid Delaet sold 7,143 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the transaction, the insider now directly owns 2,507 shares in the company, valued at approximately $376,300.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at $5,499,554.79. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,968 shares of company stock worth $8,999,632. 4.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on NBIX shares. Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Thursday, August 29th. Raymond James reissued an “outperform” rating and set a $155.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Morgan Stanley lifted their price target on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Finally, Robert W. Baird increased their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.91.

Neurocrine Biosciences Stock Down 1.5 %

Shares of NASDAQ NBIX opened at $115.08 on Thursday. The firm has a 50-day moving average price of $124.09 and a 200 day moving average price of $134.34. The stock has a market capitalization of $11.58 billion, a price-to-earnings ratio of 31.70 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 52 week low of $103.63 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.15 by ($0.52). The firm had revenue of $590.20 million for the quarter, compared to analysts’ expectations of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The firm’s revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.95 EPS. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 4.19 EPS for the current fiscal year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.